These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 7720772)
1. CNS research in the pharmaceutical industry. A personal view of how innovation could be promoted by clinical pharmacology. Horowski R Eur J Clin Pharmacol; 1995; 47(5):467-8. PubMed ID: 7720772 [No Abstract] [Full Text] [Related]
2. The extinction of drugs for clinical research: Can the ECNP medicines chest save them? Nutt D; Kilpatrick G; Hayes A Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534 [No Abstract] [Full Text] [Related]
4. New developments in neuroscience. Williams M Curr Opin Investig Drugs; 2003 Jan; 4(1):26-7. PubMed ID: 12625023 [No Abstract] [Full Text] [Related]
5. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics. Yokley BH; Hartman M; Slusher BS ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461 [TBL] [Abstract][Full Text] [Related]
6. Clinical Trials in CNS--SMi's Seventh Annual Conference. 25-26 November 2008, London, UK. Sherwood D IDrugs; 2009 Feb; 12(2):84-6. PubMed ID: 19204879 [No Abstract] [Full Text] [Related]
8. True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence. Goetghebeur PJ; Swartz JE J Psychopharmacol; 2016 Jul; 30(7):586-94. PubMed ID: 27147593 [TBL] [Abstract][Full Text] [Related]
9. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722 [TBL] [Abstract][Full Text] [Related]
10. Why is the global CNS pharmaceutical market so under-penetrated? Pardridge WM Drug Discov Today; 2002 Jan; 7(1):5-7. PubMed ID: 11790589 [No Abstract] [Full Text] [Related]
11. Mind over matter: CNS-based approaches to urological diseases. Wyllie MG BJU Int; 2004 Dec; 94(9):1389-90. PubMed ID: 15610126 [No Abstract] [Full Text] [Related]
12. Axel Unterbeck on memory, cognition and the development of CNS drugs. Interview by Steve Carney. Unterbeck A Drug Discov Today; 2005 Feb; 10(3):165-8. PubMed ID: 15708528 [No Abstract] [Full Text] [Related]
13. Digital phenotyping approaches and mobile devices enhance CNS biopharmaceutical research and development. Smith DG Neuropsychopharmacology; 2018 Dec; 43(13):2504-2505. PubMed ID: 30267015 [No Abstract] [Full Text] [Related]
14. Optimizing the discovery organization for innovation. Sams-Dodd F Drug Discov Today; 2005 Aug; 10(15):1049-56. PubMed ID: 16055021 [TBL] [Abstract][Full Text] [Related]
15. Understanding GPCR signaling in the brain- the path to CNS drug discovery. Chatenet D; Hébert TE Curr Opin Pharmacol; 2017 Feb; 32():v-vii. PubMed ID: 28417881 [No Abstract] [Full Text] [Related]
16. The top prescription drugs of 2012 globally: biologics dominate, but small molecule CNS drugs hold on to top spots. Lindsley CW ACS Chem Neurosci; 2013 Jun; 4(6):905-7. PubMed ID: 24024784 [No Abstract] [Full Text] [Related]
17. Peter Corr outlines Pfizer's approach to innovation, maximizing capabilities and delivering essential medicine. Interview by Steve Carney. Corr PB Drug Discov Today; 2005 Aug; 10(15):1017-20. PubMed ID: 16055016 [No Abstract] [Full Text] [Related]
18. Central nervous system drug development, basic, and clinical research: thinking outside the box. Klein DF; Glick ID; Shader RI J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701 [No Abstract] [Full Text] [Related]
19. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders. Macauley D; Al-Shamahi A IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499 [No Abstract] [Full Text] [Related]
20. Abstracts of the 12th Biennial Meeting of the European Behavioural Pharmacology Society, Tubingen, 2007. Behav Pharmacol; 2007 Sep; 18 Suppl 1():S1-115. PubMed ID: 17704663 [No Abstract] [Full Text] [Related] [Next] [New Search]